Homepage Top Section2

According to Pfizer, the combination of the consumer healthcare businesses had registered global sales of nearly $12.7bn in 2017. GSK said that the combination will comprise two portfolios

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to treat patients who use hemodialysis or peritoneal dialysis. It will help induce coordinated erythropoiesis, increase red blood

The partnership between C4XD and the Horizon Discovery intends to assess synthetic lethal oncology targets identified by the latter’s CRISPR-Cas9 technology. C4XD will apply its 4D shape-based chemistry

Herzuma, which is a HER2/neu receptor antagonist biosimilar to Herceptin, has been approved to treat HER2-overexpressing breast cancer for certain indications. Celltrion CEO Woosung Kee said: “Biosimilars are

The partners will combine the Morphomer platform technology of the Switzerland-based AC Immune with the clinical development expertise and commercial capabilities of Lilly in central nervous system disorders

The agreement allows both firms to resolve all litigation across the world. It will enable Alnylam to reduce the costs and distraction linked with continued litigation in various

The phase II Eagle trial is a randomized, open-label and multi-centre trial designed to assess Imfinzi monotherapy and Imfinzi in combination with anti-CTLA4 antibody tremelimumab against SoC chemotherapy

UCB will build a new £150mto £200m research and development facility as part of the total investment over the next five years. The transition to the facility will

The phase 3 MAIA study showed that the daratumumab, in combination with lenalidomide and dexamethasone (Rd), has reduced the risk of disease progression or death in patients with